We are commercializing a treatment for a severe form of corneal blindness called limbal stem cell deficiency. This rare disease causes a significant societal burden because it occurs especially in young and working age people. The treatment is based on IP-protected technology for differentiating highly potent limbal stem cells from human pluripotent stem cells, providing an unlimited source of therapeutic cells. Our technology is currently in the preclinical phase.